Novo Nordisk delivered what CFO Karsten Munk Knudsen called “one of the bigger guidance hikes we’ve had as a company” in early August 2026 — and the stock still sold off. The market’s skepticism sits at the center of a disconnect that Knudsen spent 19 minutes trying to bridge on The Top Line: between the mechanical arithmetic of the company’s second-half slowdown and the structural story of an obesity market that is expanding roughly 80% year over year in volume terms, even as Novo’s reported growth rate shrinks. The through-line of his argument: strip out the one-off rebate math and the patent expiries, and there is no demand problem, there is a comparator problem.
The Q2 beat and the mechanics behind the guidance raise
The headline numbers landed squarely above expectations: 7% sales growth and 11% adjusted operating profit growth for Q2 2026, “predominantly driven by underlying volume growth for our GLP-1 franchise, both in international operations but also in the U.S. across injectable and oral platforms,” Knudsen said. First-half adjusted sales growth came in at 2%. The guidance moved from -4% to -12%, issued at the Q1 print, to a range of 0% to -6% — a midpoint of -3%.
MetricValueQ2 2026 sales growth+7%Q2 2026 adjusted operating profit growth+11%H1 2026 adjusted sales growth+2%FY 2026 guidance (old, at Q1)-4% to -12%FY 2026 guidance (new, after Q2 beat)0% to -6% (midpoint -3%)H2 2025 favorable one-off US gross-to-net rebate adjustments~DKK 5 billion, non-repeating
The crucial nuance is that the raised guidance still implies a second-half deceleration: H1 ran at 2% growth, yet the full-year midpoint is -3%. Knudsen attributes the gap to two specific factors, not declining demand. First, a tough comparator: H2 2025 benefited from roughly 5 billion Danish kroner in favorable one-off gross-to-net rebate adjustments in the US that will not repeat in 2026. Second, semaglutide patent expiry in “a few international operations markets” — Canada and Brazil — creates a negative sales impact arriving in H2 2026. Strip those out, he argued, and the second half is “really a continuation of the volume trend we’re seeing in the first half.”
Oral Wegovy goes to Europe — and the pill keeps finding new patients
Where the patent-expiry story is about defense, the oral Wegovy launch is the offensive counterpart. The sequencing has been deliberate: US launch in January 2026, UAE in Q2, UK in July, Germany in September, with further markets to follow.
The UK number is the episode’s most striking data point: “around 300,000 patients” started the pill in “a matter of a few weeks” during July, powered “to a very high extent” by telehealth — the same dynamic that accelerated US uptake. Germany is expected to follow a similar pattern, including some of the same telehealth players, and Novo expects to be first to market with an oral obesity drug there. Pricing in Europe reflects lessons from the US most-favored-nation agreement: launching at $1.49 for the lower doses in the US “enables also finding a sweet spot for pricing in the ex-U.S. markets,” Knudsen noted.
The most strategically important data point concerns where the pill’s patients come from. An estimated 80% of oral Wegovy users are new to the obesity medication segment, with the remaining 20% switching from injectable Wegovy or competitor products. Knudsen conceded that some indirect cannibalization — patients who would otherwise have started on an injectable but chose the pill instead — is difficult to estimate, but the net effect is unambiguous: the pill is growing the category, not shifting share within it. That category, he added, is expanding roughly 80% year over year in volume terms.
Why Wall Street’s prescription data is undercounting the obesity market
Beneath the pill’s distribution model sits the episode’s subtlest issue — whether the prescription-tracking data that investors and analysts rely on reflects reality. The obesity market is more than 90% self-pay, which drives a distribution model centered on telehealth platforms. The legacy data providers, Knudsen noted, “are not fully geared to this new type of distribution setup.”
When Novo reported Q2 earnings, it included its own full-capture estimate of 265,000 weekly US Wegovy prescriptions. IQVIA’s reported data covers an estimated 60% of the market. Knudsen’s stated intent is transparency: “We try to be transparent in terms of what we see and what IQVIA captures, and then it’s really for the capital markets to take it from there.” The practical implication for analysts is that IQVIA-based prescription trends will systematically lag the true trajectory of the oral obesity market, and the widening gap is itself a signal of how fast distribution is migrating away from traditional channels.
Semaglutide patent expiry: a bounded drag, not a cliff
The second factor in the H2 guidance deceleration — generic semaglutide — is the one host James Waldron pressed hardest. Knudsen’s answer frames the erosion as both inevitable and, so far, contained. The full-year financial impact remains low single digits on the top line, a guide the company has held since last year. The regulatory mechanics matter: in Canada, generic approval triggers a significant pricing step-down required by regulations, and that is where the main financial implications sit, followed by Brazil. Initial weeks in the first markets show the brands holding volume while generics expand the market rather than replace it — the same pattern observed in India.
“First and foremost, patent expiry is part of running a pharmaceutical company, and that’s what encourages us to invest in R&D pipeline and innovate and create new and better products to the benefits of patients and society,” Knudsen said.
Operationally, Novo intends to defend its existing position: “We absolutely intend to fight for the volumes we have in the markets and then, of course, compete with the generics as they enter.” Patent expiry slots into the broader guidance story as the second of exactly two reasons the second half decelerates — a bounded, named, low-single-digit drag concentrated in two markets, not a systemic demand problem.
CagriSema: reading REIMAGINE 4 against the negative framing
If oral Wegovy is the near-term growth lever, CagriSema is the swing factor for Novo’s long-term competitive position. The narrative arc Waldron recapped is familiar: heavy initial hype, dampened expectations after studies suggested the drug may not beat Eli Lilly’s products head-to-head on weight loss, and an FDA approval decision pending. The fresh data point is REIMAGINE 4, a phase 3 study in diabetic patients, where on blood-sugar control the drug did not beat Lilly’s Mounjaro. Knudsen’s reframe is the episode’s most counterintuitive argument.
REIMAGINE 4 endpoint (patients with diabetes)ResultKnudsen’s framingWeight loss15%Cleared the noninferiority bar; “one of the key drivers in the diabetes segment beyond A1c”Blood-glucose reduction1.9 pointsNoninferiority not proven against Mounjaro, but “really good” and in line with incretin-class expectations
“I think it’s important not to take the negative lens on that because actually what the data showed is that in patients with diabetes, CagriSema lowers weight by 15%,” Knudsen said. A 1.9-point blood-glucose reduction, in his construction, sits where the incretin class should land — “being around two is where you should expect to be” — while the 15% weight loss is a distinct commercial asset in a diabetes market where weight is increasingly part of the treatment conversation. His strategic argument: the obesity market, with a billion potential patients at global scale, will fragment. Different segments will prefer different products, and CagriSema gives Novo a second product to compete across that fragmentation. He called it “a competitive diabetes product for many years to come.”
The hunt for pipeline assets — and the cost program funding it
The same discipline that frames the CagriSema defense extends to Novo’s acquisition strategy. On the morning’s press call, R&D chief Mikael Dolsten said “right now our staff are looking at multiple different assets.” Waldron pressed Knudsen on whether a deal is imminent. Knudsen declined to telegraph one — “there’s really no change” to a standing posture of hunting externally and internally, subject to four conditions.
M&A criterionKnudsen’s formulationStrategic fitFits Novo’s focus therapeutic categoriesUnmet need”It has to serve unmet needs”Scientific conviction”We believe in the science”Financial discipline”It has to be rational from a financial point of view”
The acquisition hunt is funded by a cost program running ahead of plan. Waldron stated the savings target at roughly 8 billion Danish kroner; Knudsen did not correct the figure, reporting that 9,000 employees left in 2025 and headcount is down 12,000 year over year as of the Q2 2026 report, with procurement savings pushed hard alongside. The strategic logic: the program exists to free capital for growth, not to defend margins. “Like in other industries, we cannot save ourselves to success. We can save to invest in growth and growth options, both short and long term,” Knudsen said.
Novo Nordisk’s Q2 numbers tell a story that is more legible than the stock’s recent trajectory implies. Volumes are growing across the GLP-1 franchise. Oral Wegovy is expanding the obesity market rather than re-slicing it. The second-half deceleration is a pre-announced mechanical adjustment, not a demand signal. The risks that could break that framing are equally clear: CagriSema’s FDA label and launch narrative will test whether 15% weight loss in diabetic patients carries commercial weight when Lilly’s Mounjaro sets the glucose bar higher. The UK’s 300,000-patient launch velocity in July is encouraging, but the German launch in September will reveal whether first-mover status holds and whether telehealth-driven starts convert to durable revenue. Generic semaglutide in Canada and Brazil is so far a volume-expansion story, but the pricing step-downs are permanent. And the IQVIA data gap — 265,000 weekly US scripts in Novo’s full-capture count versus an estimated 60% in reported numbers — means the street will keep squinting at a partially obscured market for some time yet.